Apyx Medical Corp (NAS:APYX)

Q2 2026 Apyx Medical Inc Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: $4.16 (+0.48%)

Transcript 10-Q8-K

Key Points

Positve

Apyx Medical Corp (APYX) reported a 22% increase in quarterly revenue to $13.9 million, driven by a 28% surge in surgical aesthetics product sales.
The company received expanded FDA 510(k) clearance for power liposuction on its Aion platform, enhancing its body contouring capabilities and driving new commercial shipments.
Apyx Medical Corp (APYX) is capitalizing on the growing GLP-1 weight-loss trend, positioning its Aion platform to address the resulting demand for skin laxity and body contouring procedures.
Clinical data presented during the quarter showed that combining Renuvion with liposuction led to higher patient satisfaction and lower revision rates, strengthening the product's value proposition.
Gross profit margin improved to 63.9% from 62.3% in the prior year, driven by a favorable product mix shift toward the higher-margin surgical aesthetics segment.
The company reaffirmed its full-year 2026 revenue guidance of $59 million to $60 million, reflecting confidence in continued growth and market adoption.

Negative

Apyx Medical Corp (APYX) reported a net loss of $3.2 million for the second quarter, though this was an improvement from the $3.8 million loss in the prior year period.
OEM segment sales decreased 12% year-over-year due to lower sales volume to existing customers, a trend the company expects to continue as it focuses on surgical aesthetics.
The company's cash used in operating activities increased to $3.5 million in the second quarter, up from $1.2 million in the prior year period, due to changes in working capital.
Gross margins are expected to face pressure in the second half of 2026 as the company ramps up production of the new power liposuction handpieces, which are initially more expensive to manufacture.
Tariffs that began affecting the company in the second half of 2025 continue to partially offset gross margin improvements, creating ongoing cost headwinds.
The company did not provide specific numbers on Aion system installations, leaving investors without a clear metric to gauge the pace of market penetration.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

APYX.OQ - Apyx Medical Inc
Q2 2026 Apyx Medical Inc Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen, and welcome to the Apex Medical2Q26 earnings conference call at this time, all lines are in a listen-only mode.

Following the presentation, we will conduct a question-and-answer session.

If at any time during this call you require immediate assistance, please press 0 for the operator, this call is being recorded on Thursday, August 6th, 2026.

I would now like to turn the conference over to Jeremy Fpper, LifeSite Advisors, please go ahead.

Thank you and welcome everyone to our second quarter 2026 earnings call.

Representing the company on the call are Charlie Goodwin, Chief Executive Officer, and Matt Hill, Chief Financial Officer of Apex.

Before we

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.